Bills: SB191, HB84, HB79, SB132, HB108, HB109, HB110, HB114, HB118, HB120, HB122, HB124, HB126, HB128, HB129, HB131

Keywords: postpartum depression, mental health, Medicaid, screening, education, maternal health, Chiropractic, Board of Chiropractic Examiners, license renewal, continuing education, election procedures, off-label, pharmacists, medical treatment, state board of pharmacy, employment protection, SB132, Alabama, controlled substances, Schedule I

Transcript Highlights:

• stuck in there that it's going to be 0.4 milligrams of total THC, that's any THC product, or any THC compound
• In fact, you lose money when you sell your pharmaceutical products.
• How do they stay in business if they're pharmacies and they're losing money selling pharmaceutical products

Keywords: 977, all

Transcript Highlights:

• And if we look at the trajectory, it's going to start compounding.
• The fact of the matter is the Industrial Commission of Arizona runs a brilliant annual pharmaceutical
• You are creating an oligopoly of pharmacy benefit managers who will manage and run pharmaceutical prices

Bills: HB2211, HB2229, HB2389, HB2403, HB2445, HB2502, HB2620, HB2813, HB2872, HB2889, HB2960, HB4028, HCR2007

Keywords: contractors, subcontractors, resident preference, public contracts, materials supply, Arizona Revised Statutes, local businesses, pregnancy resource center, pregnancy center, crisis pregnancy center, DHS, Arizona Department of Health Services, state appropriation, general fund, nonprofit grant, women's health, maternal health, reproductive health, abortion funding, pro-life

Transcript Highlights:

• Do you know how many heads of the FDA have not taken their next job with a pharmaceutical company?
• There is a problem with the pharmaceutical industry, and there's gonna be huge amounts of pushback for
• I anticipate, or I imagine, that when a drug manufacturer develops a medication or some type of compound

Bills: HB 265, HB25

Keywords: youth camp, safety regulations, advisory committee, child welfare, health standards, summer camp, camp safety, child abuse reporting, child neglect, mandatory reporting, background check, criminal history check, sex offender registry, CPR training, first aid, public health, child protection, camp operator, camp counselor, Health and Safety Code

Transcript Highlights:

• <01:34:46.719><c> because</c><01:34:47.040><c> the</c><01:34:47.280><c> insurance</c> pharmaceuticals
• </c><01:40:17.360><c> from</c><01:40:17.600><c> their</c> their pharmaceuticals from their their pharmaceuticals
• HDA is the trade association representing the nation's pharmaceutical wholesale distributors.
• But over time, these continued contribution deficiencies have a compounding effect.
• compounding compounding effect.<04:50:08.400><c> Uh</c><04:50:08.958><c> and</c><04:50:09.200><c> this

Keywords: 928, house, all

Summary: The committee first heard Senate Bill 47, sponsored by Sen. Regina Birdsell at the request of the Insurance Department. The bill would codify the department’s interpretation that a birth mother’s health insurance is the primary coverage for a newborn, unless the mother has no insurance or coverage under an employer-sponsored plan. Birdsell and Insurance Commissioner DJ Benton Court said the measure is a clarification of existing practice and intended to protect vulnerable newborns; a question from Rep. Miles clarified that if a young woman is on her parents’ policy, the newborn would generally be covered under that family coverage. The hearing on SB 47 was then closed. The committee then took up Senate Bill 121, introduced by Grant Bosi for Sen. Kevin Avard, which would require insurers to notify the Insurance Department when they stop writing an entire line of business or, in some cases, Medicare Advantage plans. Commissioner Benton Court said the bill arose from disruption in the Medicare Advantage market, where consumers, brokers, and the department were confused by carriers changing or ending offerings; he said the department wanted a simple notification requirement so it could better advise consumers. Members discussed network adequacy, county-based service areas, and the fact that the bill would make notice a condition of licensure, with possible fines or license action for noncompliance. Witness Paula Rogers of AHIP said her group supported the bill if amended, and the department indicated it would support a change from a 120-day notice period to 90 days to align with state rules; the committee planned to work on an amendment in subcommittee. Finally, the committee heard Senate Bill 247, introduced by Rep. Brian Cole, which would prohibit network exclusion of pharmacies that refuse to dispense prescriptions when PBM reimbursement is below acquisition cost. Cole argued the bill is meant to stop pharmacies from being forced to sell drugs at a loss, describing PBMs as middlemen and saying the measure is a compromise that protects local pharmacies. Members questioned whether consumers would pay more and whether pharmacies voluntarily enter PBM contracts; Cole responded that the bill would let pharmacies refuse unprofitable fills while consumers could still obtain the drug through mail order or other channels. He also said the issue has changed over time because the practice now affects a much larger share of generics and is concentrated among a few PBMs. The hearing remained open as questions continued, with no vote taken in the excerpt.

Transcript Highlights:

• reimbursement rates, clawbacks, rebates, billing, licensing, PBMs, rebates, billing, licensing, PBMs, pharmaceuticals
• We know pharmaceutical costs are driving the increase in premium rates in Massachusetts.
• We know pharmaceutical costs are driving the increase in premium rates in Massachusetts.
• H-1370 acknowledges the critical compounding of challenges that result when social risks are added to

Keywords: 995, all

Summary: The Joint Committee on Health Care Financing held a public hearing on a large docket focused on primary care, workforce development, and medical debt. Chairs Cindy Friedman and John Lawn outlined hearing procedures and noted that testimony would be taken on 17 matters. The committee first heard testimony on bills to establish a community health center nurse practitioner residency program and to strengthen mental health centers. Senator Keenan, Rep. Keefe, and health center leaders described the Worcester nurse practitioner residency as a successful pipeline and retention strategy, citing workforce shortages, training needs in community health centers, and the cost of the program. Rep. O’Day also supported the mental health centers bill, saying it would raise payment rates, improve reimbursement for behavioral health services, and help clinics retain staff and expand access. The committee then took testimony on bills to address medical debt through hospital financial assistance reform. The Attorney General’s Office, Health Care for All, Health Law Advocates, the Leukemia and Lymphoma Society, and individual patients supported the measure, arguing that hospital financial assistance policies are inconsistent, hard to find, and difficult to navigate. Witnesses said the bill would standardize eligibility criteria, create a uniform application, improve notice requirements, and expand access to discounted care up to 400% of the federal poverty level. Several personal stories described medical bills being sent to collections, confusion over insurance billing, and the burden of debt on low-income and chronically ill patients. Committee members asked about hospital concerns, the role of the health safety net, and whether the bill addressed root causes of medical debt; testimony emphasized that the proposal was meant to improve transparency and access rather than replace broader insurance reforms. The hearing also focused heavily on “Primary Care for You” legislation, H. 1370 and S. 867, which would increase primary care investment and create a new payment model. Rep. Haggerty, physicians, a patient, community health center leaders, and the Massachusetts League of Community Health Centers described a primary care crisis marked by low reimbursement, staffing shortages, long waits, burnout, and difficulty recruiting clinicians. Supporters said the bills would shift spending toward preventive, team-based care, improve access and equity, and reduce long-term costs. The Massachusetts Association of Health Plans said it was directionally supportive of increased primary care investment but warned that any new spending must stay within the cost growth benchmark and preserve existing contracting structures. The hearing ended with additional testimony on a community health center workforce and loan repayment grant bill from Rep. Stanley, and with further discussion from Dr. Alan Garo about the need for payment reform in primary care.

Transcript Highlights:

• That cost has been in excess of over $1,000 a month, or I could choose to purchase a compound.
• And compounds, I don't want to get into a debate with the compound people, so I will shy away from that
• . ...compound people, so I will shy away from that, but most feel that it's probably better if you could
• So because, based upon money, I chose to spend over $600 a month on a compound.
• Hospital costs have increased more than 265% over the past five years, and pharmaceutical costs have

Keywords: 987, senate, all

Transcript Highlights:

• Senator Westrom asked on the Senate floor whether you have any evidence that pharmaceutical companies
• Senator Westrom asked on the Senate floor whether you have any evidence that pharmaceutical companies
• Senator Westrom asked on the Senate floor whether you have any evidence that pharmaceutical companies
• Senator Westrom asked on the Senate floor whether you have any evidence that pharmaceutical companies
• </c> low-cost medications from pharmaceutical low-cost medications from pharmaceutical manufacturers<

Keywords: 918, senate, all

Summary: The meeting focused on a Minnesota Senate floor debate over a bipartisan 340B enforcement bill, with supporters arguing that the measure would require pharmaceutical companies to comply with federal and state law and continue providing discounted drugs to safety-net and rural hospitals. Senators and other speakers said the program is essential to hospital finances, especially for facilities facing operating losses and federal Medicaid cuts, and warned that without enforcement language hospitals such as Hennepin County Medical Center and rural hospitals could face severe financial harm or closure. Supporters also said pharmaceutical companies had spent heavily on media and lobbying to oppose the bill and that the Senate’s bipartisan vote showed the issue had broad support. Several speakers described how 340B revenue is used to sustain hospital services, including addiction treatment, trauma care, and other essential care in vulnerable communities. They said the program was designed to let hospitals buy drugs at low cost and bill insurers at standard rates, using the difference as a funding stream. When asked about claims that hospitals made large sums from the program, supporters said that was consistent with the program’s purpose. They also said some drug companies were not complying with 340B obligations, particularly around contract pharmacies, and that enforcement language was needed to ensure compliance. The discussion also addressed HCMC’s financial situation, with speakers saying 340B funding is not a full solution but is an important support and should not be reduced further. They rejected a proposed transparency/reporting amendment as too burdensome, while noting that federal authorities already have audit power over 340B dollars. The speakers urged the House to pass the same language, said eight Republicans joined the Senate vote, and expressed hope that the bill would advance despite concerns about House support and ongoing pharmaceutical industry opposition.

Transcript Highlights:

• 37.599><c> uh</c><02:04:37.760><c> HB192</c> I move on to HB 1192, exempting certain household pharmaceutical
• We know there are thousands, 15,000 and counting, different PFAS compounds, but this particular method
• PFAS compounds, but this particular method looked at 36 of them. So that's the sum of the 36.
• >> It depends on the PFAS compound.

Keywords: 1189, house, all

Transcript Highlights:

• We're just going to compound the challenges with the grid. So it's a real win-win for all parties.
• This includes pesticides, paints, pharmaceuticals, cleaners, and other common chemicals.

Summary: The committee held an interim work session focused first on carbon capture, utilization, and sequestration (CCUS), then on hazardous waste and extended producer responsibility (EPR). On the CCUS topic, industry and nonprofit presenters described point-source capture, direct air capture, mineralization, and geologic sequestration, emphasizing Washington’s basalt formations and state trust lands as strong candidates for storage. They argued that CCUS can help hard-to-abate industrial sectors, support jobs and investment, and provide a pathway for compliance, while also noting the need for clearer permitting, subsurface rights, pipeline authority, and storage infrastructure. Ecology and Commerce staff explained current state policy touchpoints, including Cap-and-Invest offsets and exemptions for permanently stored CO2, the public comment process underway to define “thousand-year” permanence, and how CCUS might fit within the Clean Energy Transformation Act without counting emitting generation as non-emitting. Some presenters supported more state action and primacy over federal permitting, while others warned about costs, energy use, uncertain capture performance, and the need to ensure real net greenhouse gas reductions and long-term liability protections. Members asked about public meetings, whether mineralized carbon would qualify as exempt under the Climate Commitment Act, the timeline for Ecology guidance, aquifer and water-quality concerns, energy intensity of capture systems, and liability if storage later proves problematic. Responses said Ecology’s guidance process is already underway, public meetings will be virtual, mineralized carbon would likely qualify if it meets the permanence standard, and EPA rules require storage in deep saline formations below drinking water aquifers. Industry speakers said capture energy use varies by source and concentration, and one presenter noted that some states use trust funds funded by injectors to address long-term liability. The second half of the session shifted to hazardous waste and EPR. Ecology staff reviewed existing product stewardship programs for electronics, paint, batteries, and mercury lights, and described moderate risk waste and household hazardous waste management in Washington. They highlighted that E-Cycle and PaintCare are producer-funded, that the battery stewardship program will begin in 2027, and that the mercury lamp program is in transition after its prior stewardship organization exited, prompting enforcement notices and a pending replacement plan. Ecology recommended best practices for future EPR programs, including clear producer and product definitions, full producer funding, convenience standards, annual reporting, and strong agency enforcement and plan approval authority. Local government speakers from King County and Douglas County described rising collection costs, equity and access barriers, rural travel distances, and the need for stable funding and flexible local implementation. King County said it collected over 3 million pounds of hazardous products in 2025 and supports EPR as a way to shift costs from ratepayers to producers, while Douglas County emphasized that rural residents will participate when services are accessible and that future systems should account for geography and local infrastructure.

Transcript Highlights:

• And so they have skewed the costs in the pharmaceutical market so badly that we are now running pharmacists
• But when you start talking about the senior freeze and the compounding effect of property tax over the

Bills: HR1051, HR1048, SB2074, SJR39, SJR47, SB1983, SB444, SB1503, SB1561, SB592, SB1501, SB1946, SB1567, SB1833, SB2026, SB904, SB2178, SB1651, SB1558, SB1565, SB1553, SB1257, SB65, SB1749, SB1242, SB1642, SB640, SB667, SB1436, SB1484, SB1562, SB1794, SB1644, SB1533, SB933, SB1555

Keywords: livestock, judging, Oklahoma State University, championship, agriculture, military children, recognition, community support, military families, April 15, pharmacy benefits managers, reimbursement, healthcare, prescription drugs, cost regulation, property valuation, tax limit, homestead, income threshold, elderly

Summary: The House opened with prayer, the Pledge of Allegiance, and a series of special presentations and introductions celebrating Oklahoma State University, the Cowgirl Wrestling Club, the OSU livestock judging team, military children, poster contest winners, and several visiting groups and honorees. The chamber also recognized the Doctor of the Day, Dr. Kurt Emerson, and the Nurse of the Day, Beverly Felton. Much of the floor time was devoted to OSU Day remarks, including a citation honoring the university and comments from Speaker Hilbert, Coach Eric Morris, and President Jim Hess. The House then took up Senate Bill 2074, a pharmacy benefit manager measure intended to regulate PBMs and support pharmacists. An amendment by Representative Jenkins to remove a section of the bill was tabled, and members questioned the bill extensively about reimbursement rates, consumer costs, employer options, transparency, and the impact on independent pharmacies. After debate, the bill advanced and passed the House by a vote of 87-7. Members also considered Senate Joint Resolution 39, which would place a constitutional amendment on the ballot to cap property tax growth. The measure, as amended, would set a 1.75% annual cap on homestead property tax growth and a 4% cap on other properties, with a stair-step senior freeze. The resolution drew debate over effects on local government revenue, schools, roads, jails, and inflation, but supporters argued it would provide strong taxpayer protections. The House passed the resolution 85-9 and then took the additional vote required to refer the constitutional amendment to a special election.

Transcript Highlights:

• This is compounded by poor Medicaid reimbursement, inadequate training, and lack of hospital access.
• You've got supplies and pharmaceuticals coming in after that. You've got some non-capital costs.

Transcript Highlights:

• effective and less risky than the expensive drugs. with many side effects being pushed by the pharmaceutical
• absence of clear laws, the dignity of the dead is up for grabs, and families are left with grief compounded

Bills: SB66, SB243, SB250, SB317, SB393, SB397, SB456, SB628, SB629, SB636, SB715, SB731, SB801, SB865, SB1012, SB1013, SB1015, SB1032, SB1141, SB1181, SB1224, SB1241, SB1242, SB1250, SB1266, SB1285, SB1376, SB1442, SB1449, SB1502, SB1524, SB1528, SB1551, SB1585, SB1640, SB1708, SB1844, SB1854, SB1863, SB1959, SB1965, SB2035, SB2082, SB2119, SB2138, SB2199, SB2200, SB2201, SB2245, SB2269, SB2284, SB2310, SB2357, SB2419, SB2422, SB2480, SB2514, SB2523, SB2529, SB2533, SB2541, SB2550, SB2568, SB2595, SB2605, SB2608, SB2615, SB2717, SB2721, SB2753, SB2778, SB2841, SB2846, SB2891, SB2925, SB2929, SB2933, SB3016, SB3029, SB3039, SB3044, SJR3, SJR18, SB5, SB326, SB494, SB530, SB767, SB769, SB783, SB914, SB963, SB1035, SB1197, SB1271, SB1415, SB1437, SB1619, SB1637, SB1786, SB1806, SB2312, SB29, SB1238, SB1967, SB1, SB260, SB1637, SJR36, SJR50, SJR63, SJR59, SCR12, SCR39, SCR48, SCR19, SB2023, SB62, SB666, SB847, SB284, SB854, SB1073, SB810, SB1505, SB583, SB1502, SB507, SB1434, SB1376, SB1585, SB1772, SB2016, SB1163, SB1122, SB731, SB397, SB508, SB1436, SB287, SB261, SB1882, SB393, SB1791, SB209, SB2429, SB1999, SB511, SB2309, SB510, SB1085, SB1975, SB2717, SB1262, SB1524, SB636, SB2056, SB884, SB517, SB1200, SB1845, SB1863, SB2681, SB2200, SB2199, SB2458, SB2201, SB801, SB2533, SB3014, SB3013, SB758, SB1013, SB2797, SB2119, SB2076, SB2876, SB2284, SB2929, SB2595, SB715, SB1640, SB2514, SB2753, SB1241, SB2538, SB1449, SB2529, SB2846, SB986, SB1181, SB1359, SB2550, SB2245, SB410, SB1234, SB456, SB1012, SB2926, SB2138, SB1242, SB2615, SB2310, SB1224, SB2972, SB2841, SB3016, SB1856, SB2035, SB1528, SB1141, SB1266, SB1373, SB2269, SB2480, SB672, SB2891, SB2422, SB1854, SB317, SB2539, SB2532, SB2925, SB1250, SB2082, SB2203, SB2357, SB2721, SB243, SB1285, SB2568, SB1959, SB1442, SB1454, SB2520, SB2541, SB1708, SB1237, SB1844, SB1586, SB1551, SB3039, SB2819, SB66, SB629, SB1015, SB2342, SB2903, SB2933, SB1965, SB2477, SB3029, SB2605, SB2419, SB1957, SB375, SB250, SB777, SB628, SB2523, SB2367, SB2703, SB2608, SB2778, SB3044, SB2965, SB2521, SB865, SB1032, SB2165, SB2501, SB2675, SB2452, SB2835, HB1109, HB1392, HB22, HB2525, HB3093, SB872, SB1212, SB1278, SB1588, SB1602, SB1704, SB1723, SB1833, SB1858, SB1946, SB2009, SB2177, SB2460, SB2785, SB2373, SB1660, SB614, SB867, SB1608, SB1525, SB905, SB640, SB2487, SB1698, SB383, SB705, SB748, SB1113, SB1117, SB1802, SB2340, SB2586, SB2680, SB2690, SB2994, SB2747, SB1950, SB913, SB1071, SB1086, SB1087, SB1483, SB1444, SB1553, SB1556, SB1703, SB2133, SB2297, SB2298, SB2622, SB2955, SB3059, SB2782, SB2781, SB2637, SB2633, SB2337, SB2334, SB1861, SB2043, SB1367, SB946, SB945, SB2857, SB128, SB571, SB1263, SB3058, SB612, SB2221, SB2587, SB2044, SB2363, SB2713, HB517, HB912, HB1130, HB142, HB1689, HB2018

Keywords: disability, supported decision-making, legal assistance, confidentiality, access to justice, autonomy, civil rights, advocacy, migrant labor housing, migrant housing, farmworker housing, migrant agricultural worker, agricultural labor, farm labor contractor, Texas Department of Housing and Community Affairs, TDHCA, civil penalty, housing code enforcement, sanitation, occupancy standards

Transcript Highlights:

• Then we're going to, again, talk about Medicaid pharmaceutical costs.
• But we do know that many of our pharmaceuticals and pharmaceutical components are imported.
• We're seeing a substantial increase in pharmaceutical costs.
• They're pharmaceutical cost strategies in the state of Oregon.
• Pharmaceuticals are one of those.

Transcript Highlights:

• That cost has been in excess of over $1,000 a month, or I could choose to purchase a compound.
• And compounds, I don't want to get in a debate with the compound people, so I will shy away from that
• . ...compounded medication, so I will shy away from that, but most feel that it's probably better if
• So because, based upon money, I chose to spend over $600 a month on a compound.
• Hospital costs have increased more than 265 percent over the past five years, and pharmaceutical costs

Summary: The committee first took up SB 1377, a bill on medical exemptions for school immunizations. The author and supporters said the measure was a narrow reform to restore physician discretion and reduce what they described as chilling effects from audits and license discipline; opponents from pediatric, medical, public health, and school groups argued the current system already works, protects against fraudulent exemptions, and should not be weakened. Committee members debated the data, the number of exemptions reviewed or revoked, and the effect of the proposed amendments. The bill was amended in committee, but because there was no quorum it was not formally voted on at that time. The committee then heard SB 995, the Masuma Khan Justice Act, which would create a statewide inspection and compliance framework for large private detention facilities. The author and supporters described severe conditions in immigration detention, including denial of medication, unsafe food and water, and lack of oversight, and the bill was presented as a response to those abuses. The California Hospital Association raised concerns about duplicative regulation and overlapping standards, but said it was continuing to work on a solution. The committee discussed constitutional and jurisdictional issues, and the bill was moved on a do-pass motion to the Committee on Judiciary with a 5-0 vote placed on call. Next, SB 1089 was heard, proposing expanded access through CalPERS and CalRX to GLP-1 medications for chronic weight disease and diabetes prevention. The author and supporters from the American Diabetes Association and medical groups argued the drugs are effective tools to prevent type 2 diabetes, reduce long-term costs, and improve health equity, while the author also shared personal experience with weight loss and medication access barriers. There was no opposition testimony. The bill was moved on a do-pass motion to the Committee on Labor, Public Employment, and Retirement with a 5-0 vote placed on call. Finally, the committee heard SB 1221, dealing with Murphy conservatorships for people found not guilty by reason of insanity or otherwise under criminal-mental health conservatorship. Supporters, including prosecutors and psychiatrists, said the bill addresses a gap created by a court decision and would improve public safety and placement decisions for a small population of high-risk individuals. Opponents from county behavioral health and disability rights groups warned it would turn a civil process into a quasi-criminal one, expand district attorney involvement, and disrupt bed prioritization and least-restrictive-placement principles. The discussion centered on the scope of the bill and its amendments, but no final vote was taken in the portion provided.

Transcript Highlights:

• Delta-8, Delta-10, and other chemically altered THC compounds are being sold in gas stations, vape shops
• that other pharmaceuticals like Abilify and Lamictal also.
• Take your pick of any of the pharmaceuticals that you see on TV that are meant to help with psychotropics
• Or weekly as an alternative to pharmaceuticals.
• further legal ramifications for a veteran who is going to choose something other than opioids and pharmaceuticals

Bills: SB31, SB33, SB20, SB217, SB264, SB269, SB650, SB681, SB528, SB502, SB740, SB916, SB995, SB10, SB2581, SB2570, SB3031, SB24, SB379, SB1171, SB1121, SB1120, SB1061, SB1036, SB1019, SB890, SB11, SB868, SB1188, SB1254, SB2778, SB2543, SB2443, SB1333, SB1259, SB1401, SB1404, SB2139, SB2165, SB2237, SB2268, SB1202, SB1198, SB1212, SB1451, SB1470, SB1498, SB965, SB1547, SB1667, SB1818, SB1902, SB2129, SB2078, SB2069, SB1737, SB1589, SB1318, SB387, SB1150, SB1574, SB2127, SB3034, SB860, SB1278, SCR5, SCR32, SB4, SB23, SB1762, SB34, SB60, SB706, SB1814, SB1220, SB523, SB565, SB1253, SB840, SB764, SB2383, SB2155, SB1535, SB1423, SB1566, SB1804, SB1728, SB1816, SB1952, SB75, SB2068, SB1455, SB213, SB627, SB2037, SB670, SB896, SB917, SB1184, SB971, SB1255, SB1261, SB1283, SB991, SB1733, SB21, SB231, SB739, SB1252, SB1371, SB646, SB3, SCR27, SB552, SB1405, SB1948, SB243, SJR1, SB31, SB33, SB20, SB217, SB264, SB269, SB650, SB681, SB528, SB502, SB740, SB916, SB995, SB10, SB2581, SB2570, SB3031, SB24, SB379, SB1171, SB1121, SB1120, SB1061, SB1036, SB1019, SB890, SB11, SB868, SB1188, SB1254, SB2778, SB2543, SB2443, SB1333, SB1259, SB1401, SB1404, SB2139, SB2165, SB2237, SB2268, SB1202, SB1198, SB1212, SB1451, SB1470, SB1498, SB965, SB1547, SB1667, SB1818, SB1902, SB2129, SB2078, SB2069, SB1737, SB1589, SB1318, SB387, SB1150, SB1574, SB2127, SB3034, SB860, SB1278, SCR5, SCR32, SB546, SB647, SB648, SB1493, SB1709, SB2001, HB5669, HB3115, HB5655, HB5675, HB5689, HB5690, HB5653, HB3228, HB2802, HB45, HB1318, HB5560, HB2894, HB4344, HB2775, HB33, HB 12, HB148

Keywords: SB 31, Life of the Mother Act, Texas abortion law, medical emergency, reasonable medical judgment, pregnancy complications, maternal health, life-threatening condition, ectopic pregnancy, spontaneous abortion, miscarriage, unborn child, abortion exception, abortion ban, physician liability, health care liability claim, aiding and abetting, Texas Medical Board, State Bar of Texas, continuing medical education

Transcript Highlights:

• </c> manufacturer a pharmaceutical manufacturer a pharmaceutical manufacturer<01:00:01.119><c> so</c>
• <01:01:25.160><c> company</c> pharmaceutical company pharmaceutical company sitting<01:01:26.920><c>
• </c><01:02:44.880><c> products</c> coupons around pharmaceutical products coupons around pharmaceutical
• Pharmaceuticals represent a significant part of the spend on health care provision, and the pharmaceutical
• There were no pharmaceutical manufacturers there, but this bill is really about pharmaceutical manufacturer

Keywords: 1191, senate, all

Transcript Highlights:

• to re-shore very critical supply chains back to the United States of America, not only through pharmaceuticals
• Not only through pharmaceuticals, but also through critical minerals and materials and metals.
• So we manufacture various high-purity inorganic and organic salts for nutrition, food, pharmaceuticals
• Just a little background: the API Innovation Center—API stands for active pharmaceutical ingredients—is
• They work in partnership with UMSL to help create new efficiencies in pharmaceutical production.

Summary: The committee first called the roll and established a quorum, then heard Senate Bill 1553, sponsored by Senator Curtis Gregory. The bill is aimed at reshoring critical supply chains to the United States through tax credits and related incentives for production of pharmaceuticals, critical minerals, materials, and metals. Gregory said the Senate version added clarifying language tying eligible materials to federal critical-materials and FDA lists. Witnesses in support described the bill as a national security measure and an economic development tool for Missouri, citing dependence on China and India for medicines and materials, forced labor concerns in cobalt supply chains, and examples of Missouri companies and institutions already working in pharmaceutical and mineral production. Several supporters noted the bill’s incentives would be difficult to use without additional federal support, and one witness said the transferable tax credits were a key strength, though the scope could be narrowed in the future. Support testimony came from Douglas Jost of Jost Chemical Company, Jared Hankinson of the Missouri Chamber of Commerce and Industry, Matt Thompson of the API Innovation Center, Michael Givens of Doe Run Company, and Matthew Smith of Associated Industries of Missouri. Their comments emphasized supply-chain vulnerability, national security, and Missouri’s existing manufacturing base. No opposition or informational testimony was presented, and there were no substantive questions after the witnesses. The committee then moved into executive session and voted unanimously, 9-0, to report Senate Bill 1553 do pass.

Transcript Highlights:

• This expansion was done with the agreement of the pharmaceutical industry in order to have a place at
• </c><00:08:40.680><c> industry</c> agreement of the pharmaceutical industry agreement of the pharmaceutical
• </c><00:26:28.279><c> iCal</c> entirely supported by pharmaceutic iCal entirely supported by pharmaceutic
• </c> not one single pharmaceutical not one single pharmaceutical manufacturer<00:27:01.640><c> in</c>
• The pharmaceutical company agreed to that. For whatever reason, they were squeezed.

Keywords: 00:00 Introductions 02:46 Roll Call 03:35 Discussion on SB 14 46:13 Vote on SB 14 48:07 Discussion on SB 17 50:38 Vote on SB 17, 958, all

Summary: The Senate Standing Committee on Health Services opened with the chair welcoming several new members and outlining session rules: hearings would start and end on time, the committee would limit the number of bills heard each meeting, prioritize bills heard during the interim, and generally avoid using the consent calendar except in extreme circumstances. The committee then briefly considered administrative regulations, which were treated as approved if members had no questions. The main item was Senate Bill 14, a measure addressing the 340B drug discount program. The chair said the bill had already passed the Senate in a prior session and had been heard in interim, so he did not present it again. He described the bill as prohibiting drug manufacturers from discriminating against 340B covered entities by refusing 340B pricing when the same drug is offered at that price in the state. He also said the committee would not debate the federal 340B program itself, but would hear testimony on the bill. Hospital leaders and Kentucky Hospital Association representatives testified in support, arguing that 340B savings are essential to rural hospitals, oncology services, transportation support, chronic care, addiction recovery, and new service lines such as chemotherapy and hepatitis treatment. They said the program helps keep care close to home and that manufacturer restrictions on contract pharmacies have reduced access and cost hospitals millions. Opponents from BIO Kentucky and the National Alliance of Healthcare Purchaser Coalitions argued the bill would expand federal law beyond Congress’s intent, create administrative burdens, and not lower patient out-of-pocket costs. The chair repeatedly pressed opponents to address why Kentucky should be denied the same 340B pricing available in other states. No vote on the bill was taken in the portion provided.

Transcript Highlights:

• Same thing pharmaceutical industry, we need the pharmaceuticals, but we don't need to pay exorbitant
• Same thing pharmaceutical industry, we need the pharmaceuticals, but we don't need to pay exorbitant
• Same thing pharmaceutical industry, we need the pharmaceuticals, but we don't need to pay exorbitant
• Same thing pharmaceutical industry, we need the pharmaceuticals, but we don't need to pay exorbitant
• Same thing pharmaceutical industry, we need the pharmaceuticals, but we don't need to pay exorbitant

Keywords: 918, senate, all

Summary: The interview focused on Senate File 3612, which the senator described as “patient-centered care” legislation for Minnesota’s Medicaid and MinnesotaCare programs. He said the bill would remove private insurers and HMOs from administering those public programs, replace them with a state contract for claims processing and administrative services, and shift care coordination directly to primary care clinics, counties, and nonprofits. He argued the current managed-care system creates churn, prior-authorization barriers, and fragmented care, and said providers should manage care rather than insurers. The senator repeatedly cited Connecticut as a model, saying that state moved away from managed care, improved primary care participation, and saved money. He also argued Minnesota’s current system lacks transparency and may be overpaying health plans, pointing to fraud concerns and a past example in which UCare returned money to the state after an overpayment. He said the bill would improve accountability, make fraud easier to detect, and could save taxpayers billions, though he emphasized his main goal was better care rather than savings. On support and prospects, he said the bill has backing from the governor and the American Cancer Society but currently only DFL co-authors. He said he does not expect it to become law this year because the fiscal note and details are still pending, and he does not expect insurance companies to support it. He added that he is open to discussion but sees the insurers as fundamentally opposed. The interview ended with him saying workers in insurance and claims processing should be treated fairly and offered retraining or dislocated-worker support if broader reforms reduce their roles.